October 02, 2005

CATIE study: What's It mean for Schizophrenics and Bipolars?

In recent post, I referred to the landmark CATIE study. I do not use the term landm ark lightly: This is the first study I know of that has tracked schizophrenics over a long time period (18 months vs. hte usual 4-8 week study that meds go through) and measured rates of discontinuation with atypicals as compared to an old, conventional antipsychtoic. The atypicals under study were Zyprexa, Seroquel, Risperdal and Geodon. The conventional antipsych was Trliafon, a med that was popular in the 1970s.

The atypicals have been used agressively in chronic schizophrenics since the late-1990s. In the last five years, they've also been used just as aggressively among bipolars. The CATIE study did not study their use among bipolars. In my mind, given that dosages of atypicals given to schizophrenics and bipolars are roughly equivalent, I believe that this study has implications for bipolars.

The total market for antipsychotics is $10 billion a year. About 90 percent of that comes from atypicals.

So what did the study reveal? That atypicals suck, basically. That they are far from the miracle drugs their makers have pimped them out as being. That schizophrenics stopped taking them because of their rotten side effects (weight gain being prime among those). That when the patients in the study were taking them, the atypicals proved to be about as powerful at treating schizophrenia as was the comparatively ancient Trilafon.

The rates of discontinuation for these meds were truly staggering--74 percent for the all of the meds taken together. The lowest rate of discontinuation was for Zyrexa (64 percent). The worst was Seroquel (82 percent). As the study stresses, patients were not just discontinuing meds because they felt like it, but in consultation with physicians directing the research.

I am not surprised by these results. I've interviewed several hundred people who've taken antipsychotics. The majority have reported going off the meds due to side effects such as weight gain (20 to 30 pounds a year) and what I've dubbed "heavy head," which is that lovely foggy mind you get from taking these meds--much as if you had downed a fifth of whiskey the night before.

What was equally unsurprising to me was that about 25 percent of patients taking the atypicals ceased treatment because the meds did little to addressing the underlying schizophrenia. It's a seldom discussed, but often whispered reality in psychiatry that meds don't perform very well for anywhere from 30 percent to 40 percent of patients.

Miracle drugs my ass.

I've already mentioned in another post that I believe this means that the Pharma companies have no choice but to cut their prices for these very expensive meds. I'll take that up again in a future post.

Note: After briefly being available for free on the New England Journal of Medicine's website, it now costs to access the study. I'll try to get a .pdf file of the study from someone within a few days and post the file or a link to it on this site. After all, this study was paid for with $42 million in taxpayer funds. Big Pharma didn't contribute a dime (ok, they contributed meds for the study). So I am at a loss as to why NEJM considers it proprietary.

Here's a link to the National Institute of Mental Health's press release on the study. Most news accounts of the study were so lame that I won't link to them.

Posted by Philip Dawdy at October 2, 2005 11:37 PM
StumbleUpon Toolbar del.icio.us Digg it reddit

pic1.jpg

Patient Blogs. Sites.
Doctor Blogs. Sites.
Activists. News.
Social Networking. Forums.
Science. Big Pharma. Ethics.
Current Affairs
Seattle Stuff
Smoking. Stuff.

Info
About Furious Seasons
Email
Other Articles
ZYPREXA Documents
Alt ZYPREXA Documents Source
Blakemore-Brown Transcript

 Subscribe in a reader

Search


Recent Entries
$99 Left
$114 To Go
Winter Fundraiser, $134 To Go, Final Day
Ruth Lilly, Eli Lilly Heiress, Prozac Beneficiary Dies At 94
Winter Fundraiser, Final Day, Less Than $200 To Go
UCLA Psychiatrist Criticizes DSM-5
Winter Fundraiser, Barely $200 To Go
Most Popular Posts Of 2009
Winter Fundraiser, Less Than $300 Left, Let's Wrap It Up
Senate Health Care Bill Contains $1.25 Billion Gift To Sen. Stabenow
Travel Day, Comment Approval May Be Intermittent
Winter Fundraiser, Close But Stalled
Senate Health Care Reform Bill Contains Controversial MOTHERS Act, Abortion Study
Adult ADHD And Sleep Problems
Vic Chesnutt Dead At 45, Possible Suicide
Recent Comments
Archives
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
March 2006
February 2006
January 2006
December 2005
November 2005
October 2005
September 2005
Resources
Mental Health America
National Alliance on Mental Illness
Depression and Bipolar Support Alliance
National Institute of Mental Health
McMan Web
Powered by
Movable Type 3.2